February 16, 2016

Creating Hope with New Research and Expanding Programs

We are thrilled to announce that Dr. A. James Moser, Executive Director of the Institute of Hepatobiliary and Pancreatic Surgery at Beth Israel Deaconness Medical Center will be attending our Annual Sideline Pancreatic Cancer Dinner for the 7th year in a row. He has never missed this event since we started hosting it in 2010!

New research, new treatments, early detection and increasing patient awareness are helping prolong and improve the lives of those with pancreatic cancer. Many of these important developments are happening  at the Cancer Center at Beth Israel Deaconess Medical Center.

BIDMC has recently added significant new clinical and research faculty to its pancreatic cancer research and treatment roster and expanded on existing expertise. Manuel Hidalgo, MD, PhD, a distinguished physician-scientist with a career in pancreatic cancer, will arrive at BIDMC in November 2015 to serve as Director of the Leon V. & Marilyn L. Rosenberg Clinical Cancer Center and chief of the Division of Hematology/Oncology. Hidalgo (on left, in picture above) has developed therapeutic agents for pancreatic cancer as well as a platform for drug screening, biomarker development and the creation of personalized therapies.

This is a segment from the article “7 Reasons for Hope in the Fight Against Pancreatic Cancer,” which was based on Dr. Moser’s research.